Meeting ReportMolecular Targeting Probes-Radioactive & Nonradioactive - Dosimetry & Image Analysis
Radiation Dosimetry of Actinium (Ac-225) Rosopatamab Tetraxetan (Ac-RT): Anti-PSMA antibody labeled with an alpha emitter for targeted therapy of metastatic castration resistant prostate cancer (mCRPC).
Shankar Vallabhajosula, Bin He, Scott Tagawa and Neil H. Bander
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 241726;
Shankar Vallabhajosula
1Weill Cornell Medicine and Convergent Therapeutics
Bin He
2Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid)
Scott Tagawa
3Weill Cornell Medicine/Cornell University
Neil H. Bander
4Weill Cornell Medicine
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
Radiation Dosimetry of Actinium (Ac-225) Rosopatamab Tetraxetan (Ac-RT): Anti-PSMA antibody labeled with an alpha emitter for targeted therapy of metastatic castration resistant prostate cancer (mCRPC).
Shankar Vallabhajosula, Bin He, Scott Tagawa, Neil H. Bander
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241726;
Radiation Dosimetry of Actinium (Ac-225) Rosopatamab Tetraxetan (Ac-RT): Anti-PSMA antibody labeled with an alpha emitter for targeted therapy of metastatic castration resistant prostate cancer (mCRPC).
Shankar Vallabhajosula, Bin He, Scott Tagawa, Neil H. Bander
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241726;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.